Visability during arthroscopic shoulder surgery: influence of epinephrine

Visability during arthroscopic shoulder surgery: influence of epinephrine - Visability during arthroscopic shoulder surgery: influence of epinephrine

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON38382

Enrollment

126

Registered

2010-07-07

Start date

2010-09-10

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

impingement syndrome shoulder tendon

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Patients that are willing and able to participate in the study protocol - Patients in need of arthroscopic shoulder surgery based on; a Bankart- or SLAP-lesion, a rotator cuff lesion, an impingement syndrome and or AC-joint pathology.

Exclusion criteria

Exclusion criteria: - patients with known cardiac diseases/ arrhithmia - age under eighteen years - language barrier - mental disabilities - Uncontrolled hypertension (* 180/110) - Hypokalaemia - Atopic asthma - Constitutional allergy - Sulphite allergy - increased surgical risk( ASA >3)

Design outcomes

Primary

Measure	Time frame
The difference in intra-operative clarity of the visual view between epinephrine and placebo subjects in: Mean VAS score; the main study parameter is a 2-point difference (20 %).	—

Secondary

Measure	Time frame
Difference in mean blood pressure, potential cardiovasculair adverse reactions and serum epinephrine levels.	—

Countries

Netherlands

Outcome results